China Resources unit to take RMB5.66B stake in Lier Chemical

What's the deal? China Resources Pharmaceutical GroupDealroom has a profile for this one. Try Dealroom → has agreed to acquire a 23.50% stake in Lier ChemicalDealroom has a profile for this one. Try Dealroom → for about RMB5.66 billion through its subsidiary CR Double-CraneDealroom has a profile for this one. Try Dealroom →. The purchase would make it Lier Chemical's largest shareholder and turn the company into a non-wholly-owned subsidiary.

How is it structured? CR Double-Crane is buying the shares from Jiuyuan Group and Huacai Technology. The deal is classified as a discloseable transaction under Hong Kong listing rules and does not require shareholder approval.

What each side does: China Resources Pharmaceutical is a Hong Kong-listed group that manufactures and distributes medicines and healthcare products, with CR Double-Crane serving as its investment and operating arm. Lier Chemical is the acquisition target within the wider life sciences and chemicals value chain.

What's the endgame? The group uses strategic equity stakes to deepen its presence across the pharmaceutical and chemical supply chain. If completed, the deal would tighten that integration, potentially boosting operational synergies and securing upstream resources in mainland China and Hong Kong.

What could go wrong? The transaction remains conditional on agreed precedents, so completion is uncertain. The group has urged investors to exercise caution.

The signal: The move reflects a strategy of vertical integration, with a healthcare group reaching upstream into chemicals to reinforce its industry position. China Resources Pharmaceutical currently carries a market capitalisation of HK$30.16 billion.

Read more: TipRanks

Image credit: roy.luck